Previous Close | 0.1500 |
Open | 0.0000 |
Bid | 0.1600 x N/A |
Ask | 0.2000 x N/A |
Day's Range | 0.0000 - 0.0000 |
52 Week Range | |
Volume | |
Avg. Volume | 18,789 |
Market Cap | 11.481M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0800 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is very pleased to announce that its joint venture company with leading Chinese biotech company Sansure Biotech Inc. ("Sansure"), Hunan Sanway SepSMART Ltd. ("SepSMART"), which is based in Changsha, China, has obtained its business license and is now formally registered in China, which marks the final step for completion of the definitive joint venture agreement (the "JV Agreement") signed on October 27, 2
Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that it is holding an online webinar on March 22, 2024, at 4:00 pm EST to provide significant updates on the company's latest milestones.
In a recent presentation to the US Biophysical Society in Philadelphia1, Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) CEO Dr. Bob Hancock announced how the ground-breaking use of artificial intelligence (AI) has allowed the development of new and improved treatments for biofilm infections.